The Surefire® Infusion System (SIS) 025M & 025L

In a series of small retrospective and prospective studies, tumor feeding vessels were identified and selected. Using SIS, therapeutics were infused against vascular resistance, driving therapy into the liver tumor tissue while decreasing exposure to normal tissue.1,2 Constructed for excellent pushability, the SIS supports accurate placement with improved levels of control. The ultra-thin, pliable and segmented construction, along with a hydrophilic coating, reduces friction for excellent tracking performance. The soft tip is tapered to offer easy access to the target. Designed for dynamic movement, the SIS' patented tip expands during infusion to support a pressure increase. Fluid dynamic modeling demonstrated that the SIS harnessed pressure from infusion to create flow within vasculature,3 and overcame barriers to therapy delivery as shown in a retrospective clinical study of therapeutic distribution in excised liver tumors.1

Which SIS is Right for You?

SIS 025M & 025L

Available in two different sizes, the SIS 025 has a flexible construction with a larger lumen for improved flow during infusion.

Usable Length - 120 cm
ID - 0.025"
Proximal Distal Tip/OD - 3.7 F / 3.4 F
025M Vessel size - 2.0 - 4.0 mm
025L Vessel size - 4.0 - 6.0 mm

SIS Radial

The increased length of the SIS, available in all sizes, offers flexibility for radial artery access procedures. Radial access procedures can help increase patient comfort, speed recovery and lower the risk of potential post-procedure complications.

Usable Length - 150 cm
Available in 025M & 025L

Ready to Order?

Our team is here to support you. Place a domestic or international order, connect with your local Trisalus Life Sciences sales representative or learn more about our products.

Send your PO to:
Or call us at: + 1 888 321 5212

  1. Titano et al Study Design: A retrospective, single-center study included 88 treatment-naive patients with solitary HCC tumors <6.5 cm who underwent treatment utilizing either SIS (n = 18) or standard EH microcatheters (n = 70). Twenty-three patients (5 SIS, 18 EH) received a liver transplant during the study, with 1 SIS and 6 EH patients excluded from the tumor necrosis analysis for receiving subsequent therapies prior to transplant. A pathologist performed a blinded review of the liver explant specimens to assess tumor necrosis and treatment distribution. Pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in SIS explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002). Titano JJ, et al. Cardiovasc Intervent Radiol. 2019;42:560-568.
  2. Pasciak et al Study Design: A prospective study including 9 patients with unresectable liver cancer who were enrolled for the treatment of HCC (n = 6), liver-dominant metastatic disease (n = 2) or intrahepatic cholangiocarcinoma (n = 1). Each patient was treated via standard EH microcatheter or SIS. Decreases in hepatic non-target embolization were found in all patients when the microvalve catheter was used (mean 42%; σ=19%), representing a 24%–89% reduction. Increased tumor deposition was also noted in all patients (mean 68%; σ=20%), representing a relative increase of 33%–90%. Both findings were statistically significant (P<0.05). Pasciak AS, et al. J Vasc Interv Radiol. 2015;26:660-669.
  3. Durham Study Design: This laboratory study evaluated a microvalve infusion catheter vs a standard end-hole microcatheter. A hydraulic circuit representing physiological vasculature was used to empirically investigate the ability of the microvalve infusion catheter to selectively pressurize distal vasculature using both embolic and viscus media and verify computational model predictions. The Windkessel model provides a mathematical analogue of the behavior of the system in vivo. Durham E, Jaroch D, Hunter K. Poster presented at: World Conference on Interventional Oncology (WCIO); May 6-9, 2015; New York, NY.

LHS 011921es